Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.60 |
| ▸ | JAK1 | P23458 | 3/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | JAK3 | P52333 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | TYK2 | P29597 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.55 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2499030 | 0.89 | BRD4 (0.59) | BRD4JAK1HDAC1JAK2JAK3 | |
| SCHEMBL2497734 | 0.88 | KDM4E (0.64) | BRD4JAK1HDAC1JAK2JAK3 | |
| SCHEMBL2498311 | 0.86 | POLB (0.53) | BRD4JAK1HDAC1JAK2JAK3 | |
| SCHEMBL31745353 | 0.83 | JAK1 (0.59) | BRD4JAK1HDAC1JAK2JAK3 | |
| SCHEMBL2498482 | 0.83 | BACE1 (0.63) | BRD4JAK1HDAC1JAK2JAK3 | |
| SCHEMBL4254804 | 0.81 | AXL (0.64) | JAK2JAK3LTA4HPTK2HRH3 | |
| SCHEMBL5686484 | 0.81 | EGFR (0.54) | BRD4JAK1HDAC1JAK2JAK3 | |
| SCHEMBL6442924 | 0.80 | PSMB1 (0.77) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL2499009 | 0.80 | LTA4H (0.62) | BRD4JAK1HDAC1JAK2JAK3 | |
| SCHEMBL5995982 | 0.80 | BRD4 (0.54) | BRD4JAK1HDAC1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008008234-A1 | 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | BRD4 828/4885JAK1 78/4885HDAC1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.